Adherence is important to maximize the benefits of adjuvant therapy. Unfortunately studies that measure adherence (pill counts, bottle monitors, prescription records) suggest that many (as many as 40%) of patients discontinue therapy or take <85% of planned doses within the first 5 years. I ask o...

I agree with @Kathy Miller; adherence and persistence to endocrine therapy is a challenge in the management of HR+ breast cancer. I also use open-ended questions. Careful assessment of side effects is important, as I think they are the most common cause of discontinuation of endocrine therapy. While...